Ars Pharmaceuticals, INC 8-K filings

ARS Pharmaceuticals announced a strategic pivot towards targeted provider engagement for its neffy product, alongside reporting Q2 2026 financial results, including $26.2 million in U.S. neffy net product revenue.

ARS Pharmaceuticals announced the resignation of a board director and the departure of its Chief Medical Officer, effective July 15, 2026, with associated severance payments.

ARS Pharmaceuticals announces immediate CEO transition with Donn Casale appointed as Chief Executive Officer, replacing Richard Lowenthal.

ARS Pharmaceuticals stockholders re-elected three directors and ratified the appointment of Ernst & Young LLP.

ARS Pharmaceuticals announced first quarter 2026 financial results, highlighting $22.7 million in total revenue and providing updates on neffy's commercialization, including progress with CVS Caremark and international approvals.

ARS Pharmaceuticals announced the appointment of Donn Casale as President, effective June 1, 2026, with a compensation package including a $575,000 base salary and a significant stock option grant.

ARS Pharmaceuticals reported robust third-quarter 2025 financial results, driven by significant neffy U.S. net product revenue and strong commercial launch progress, supported by a substantial cash position.

ARS Pharmaceuticals, Inc. has entered into a credit agreement for up to $250 million in term loans to fund product development and general corporate purposes.

ARS Pharmaceuticals received a Paragraph IV notice from Lupin Inc. for a generic version of its neffy epinephrine nasal spray, prompting a patent infringement defense.

ARS Pharmaceuticals reports strong second quarter 2025 financial results, driven by significant growth in neffy U.S. net product revenue and expanding global market access.

ARS Pharmaceuticals, Inc. announced the successful election of four Class II directors and the ratification of Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

ARS Pharmaceuticals announces first quarter 2025 financial results, highlighting $7.8 million in U.S. net product revenue from neffy and progress in its commercial launch.

ARS Pharmaceuticals partners with ALK-Abell to co-promote Neffy, an epinephrine nasal spray, targeting pediatricians and other prescribers in the U.S.

ARS Pharmaceuticals announces positive financial results for 2024, highlighted by the successful launch of Neffy and strategic collaborations, positioning the company for continued growth.

ARS Pharmaceuticals announces FDA approval of Neffy 1 mg nasal spray for emergency treatment of allergic reactions in children aged four and older weighing 15 to under 30 kilograms.

ARS Pharmaceuticals reports preliminary Q4 2024 net product revenue of $6.5 million for Neffy, its epinephrine nasal spray, and sets ambitious goals for 2025.

ARS Pharmaceuticals announced its third quarter 2024 financial results, highlighting the ongoing commercial launch of neffy in the U.S. and a significant licensing agreement for global expansion.

ARS Pharmaceuticals has entered into a collaboration, license, and distribution agreement with ALK-Abell A/S for the commercialization of its nasal epinephrine product, neffy, outside of select territories.

ARS Pharmaceuticals has entered into a supply agreement with Nuova Ompi S.r.l. for the supply of glass microvials to support the manufacturing and commercialization of Neffy.

ARS Pharmaceuticals has amended its manufacturing agreement with Renaissance Lakewood, LLC, extending the term and revising termination provisions for its Neffy nasal spray product.

ARS Pharmaceuticals announced FDA approval for neffy, an epinephrine nasal spray for emergency treatment of allergic reactions, with a US launch expected within eight weeks.

ARS Pharmaceuticals is progressing towards potential FDA approval for its epinephrine nasal spray, neffy, while also reporting its second quarter 2024 financial results.

ARS Pharmaceuticals has updated its corporate presentation, emphasizing the potential launch of its needle-free epinephrine product, neffy, and its market opportunities.

ARS Pharmaceuticals' EURneffy nasal spray for anaphylaxis treatment receives a positive recommendation from the European CHMP, while the company prepares for a potential US launch in the second half of 2024.

ARS Pharmaceuticals held its 2024 Annual Meeting of Stockholders, electing three Class I directors and ratifying Ernst & Young LLP as its independent auditor for the fiscal year ending December 31, 2024.

ARS Pharmaceuticals is advancing its needle-free epinephrine product, Neffy, towards a potential US launch in the second half of 2024, supported by positive clinical data and strong market potential.

ARS Pharmaceuticals reports progress on regulatory approvals for its neffy nasal spray and provides a financial update for the first quarter of 2024, highlighting a strong cash position.

ARS Pharmaceuticals is preparing to submit its response to the FDA for its neffy nasal spray in early Q2 2024, following successful trial results and reporting a strong cash position.

ARS Pharmaceuticals reports a strong cash position of $228 million as of December 31, 2023, and anticipates key regulatory decisions for its epinephrine nasal spray, Neffy, in the coming months.